Assessment of the PARP inhibitor talazoparib photosafety profile

Biomed Pharmacother. 2023 Nov:167:115593. doi: 10.1016/j.biopha.2023.115593. Epub 2023 Oct 2.

Abstract

Talazoparib (TLZ) is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor employed for the treatment of breast cancer. This drug displays an absorption band in the UVA region, and therefore investigation of the possible phototoxic side-effects associated to its administration results of enormous relevance. In this context, we describe here a photochemical and photobiological study to ascertain the photosafety profile of TLZ. Concerning transient species, the singlet and triplet excited states of TLZ were detected by fluorescence (λmax em = 440 nm) and laser flash photolysis experiments (λmax abs = 400 nm), respectively. Remarkably, TLZ irradiation with UVA light in aqueous solution resulted in formation of a stable photooxidated product, TLZ-P, whose absorption band is extended until the visible region. From in vitro experiments, phototoxicity was revealed for the parent drug by neutral red uptake (NRU) assays, with a PIF value of ca 7; besides, TLZ induced formation of reactive oxygen species (ROS) and produced significant damage to both proteins and DNA. By contrast, the singlet and triplet excited states of TLZ-P were not detected, and no photodamage was observed in the NRU experiments. Overall, the results indicate that TLZ induces phototoxicity, whereas its photoproduct exhibits photosafety.

Keywords: Comet assay; Fluorescence microscopy; Photoproduct; Phototoxicity; Protein photooxidation; Reactive oxygen species.

MeSH terms

  • Dermatitis, Phototoxic*
  • Humans
  • Light
  • Pharmaceutical Preparations
  • Photosensitizing Agents
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Reactive Oxygen Species / metabolism

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • talazoparib
  • Reactive Oxygen Species
  • Photosensitizing Agents
  • Pharmaceutical Preparations